Vinay Prasad's unique ability to attract criticism — even when his bosses, including the president, wanted him to keep his ...

A federal advisory committee on autism issues has canceled plans for its first public meeting since new members were ...

A federal appeals court will hear arguments Friday in the Trump administration's effort to subpoena patient records on gender ...

For many religious objectors, including Amish, vaccination rejection is a situational interpretation of religious doctrine, ...

Recent decisions at the FDA threaten to turn its disagreements with the drugmaker UniQure into another political headache for ...

Stand Up For Science has become a formal organization and adopted a new strategy that's more confrontational with grassroots ...

In this week’s STATus Report, host Alex Hogan explains why weight loss pills were so much harder to develop than injectables.

Trump wants to focus on his efforts to lower drug prices, but the TrumpRx website is falling short of his promises.

Someone seems to have altered the Personal Genome Project’s profile page believed to belong to Epstein to indicate he provided consent to join the study Jan. 31, 2026.

Vinay Prasad, a top official at the Food and Drug Administration who has been at the center of recurring public controversies, is exiting the agency for a second time. Prasad will leave the FDA at the ...

Immediately after U.S. health officials linked Tylenol to autism, the drug's use in pregnant women visiting ERs dropped, new ...

China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more crowded ...